These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination.
    Author: Ma R, Du JL, Huang J, Wu CY.
    Journal: Biochem Biophys Res Commun; 2007 Sep 21; 361(2):537-42. PubMed ID: 17662694.
    Abstract:
    In the present study, we tried to evaluate the ligands for Toll-like receptor 7 (TLR7) (R-848) and TLR 9 (CpG ODN) as adjuvants to augment the cellular and humoral immune responses as well as the generation of long-lasting immune memories following the vaccination with HBsAg in mice. The immune responses were assessed by enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunospot (ELISPOT), and fluorescence-activated cell sorter (FACS) at the total and at the single-cell levels. Our results showed that CpG ODN or R-848 could enhance HBsAg-specific humoral and cellular immune responses following boosts. When R-848 in combination with CpG was used as adjuvants, the immune responses to HBsAg were further strengthened. Additional analysis demonstrated that the majority of the long-lasting HBsAg-specific T cells displayed effector memory phenotype. Taken together, our results imply that CpG ODN and R-848 may be the candidates as adjuvants for use in prophylactic and therapeutic hepatitis B vaccine.
    [Abstract] [Full Text] [Related] [New Search]